Abstract: Based on the data for compounds known from the literature to be active against various types of Ser/Thr kinases, a general pharmachophore model for these types of kinases was developed. The search for the molecules fitting to this pharmacophore among the ASINEX proprietary library revealed a number of compounds, which were tested and appeared to possess some activity against Ser/Thr kinases such as Aurora A, Aurora B and Haspin. Our work on the optimization of these molecules against Aurora A kinase allowed us to achieve several hits in a 3-5 nM range of activity with rather good selectivity and Absorption, Distribution, Metabolism, and Excretion (ADME) properties, and cytotoxicity against 16 cancer cell lines. Thus, we showed the possibility to fine-tune the general Ser/Thr pharmacophore to design active and selective compounds against desired types of kinases.
Introduction
Serine/threonine protein kinases are enzymes that phosphorylate the OH group of serine or threonine. Among more than 500 human protein kinases, at least 125 appeared to be serine/threonine kinases (STK) [1] . Inhibitors of Ser/Thr kinases can possess potential therapeutic uses, from treating cancer to immune disorders. Since they were found in a number of mycobacterial organisms, they can be also used for treatment of bacterial infections such as tuberculosis.
A number of attempts have been made to construct a pharmacophore model for various Ser/Thr kinase inhibitors, such as serine/threonine receptor kinase (STPK) inhibitors of tuberculosis, mTor kinase inhibitors, Aurora A and B inhibitors, B-Raf inhibitors, etc. [2] [3] [4] [5] [6] [7] [8] . Some of these models are based on the structure-based approach, i.e., docking [3] . Although docking is a promising tool for drug discovery, not all kinases (e.g., tuberculosis PknA) have an X-Ray-resolved structure, and, therefore, preliminary modeling of the binding site is necessary. This results in "double step prediction": first the modeling of the binding site is done, followed by docking, which in turn decreases the obtained hit rate. Another group of these models has been developed based on the ligand-based approach [4] [5] [6] [7] [8] . In general, a more-or less-wide group of molecules is to be aligned and the common structure features are elucidated. Usually, common structure features are developed into more general pharmacophore models [4] [5] [6] [7] .
All cited articles are devoted to the search for specific pharmacophore models targeted to a specific group of kinases. We hypothesized that it is possible to find some general features of all serine-threonine inhibitors and to construct a general pharmacophore model. Then this general model might be adjusted to any specific kind of serine-threonine kinase. To verify our hypothesis and the validity of the design, a series of compounds belonging to this scaffold were tested against several Ser/Thr kinases available in-house: Aurora A, Aurora B and Haspin kinases. The results for the most active compounds are shown in Table 1 . Application of this general pharmacophore model to the ASINEX proprietary library allowed us to find a scaffold fitting to its requirements. This scaffold consisted of a thiazole group connected through an amino group to a nitrogen-containing six-member aromatic cycle, which in turn was bound to a pyrrolidine or piperidine ring directly or via a short linker. In this scaffold, thiazole and saturated cycles served as a hydrophobic group, while the middle-positioned six-member cycle presented a source for H-bond donor or acceptor projections (if one or more "A" moieties in the ring means N).
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Experimental Section

Synthesis of Compounds
General Procedure of Buchwald Reaction
A mixture of aryl bromide or aryl chloride (1 mmol), aromatic amine (1 mmol), 9,9-dimethyl-4, 5-bis(diphenylphosphino)xantene (0.029 g, 0.05 mmol), tris(dibenzylideneacetone)dipalladium(0)-chloroform complex (0.026 g, 0.025 mmol), Na 2 CO 3 (0.159 g, 1.5 mmol) in toluene (20 mL) and water (1 mL) was stirred at 140˝C under argon atmosphere in microwave reactor for 2 h. The resulting mixture was cooled down, diluted with water and extracted with ethyl acetate. The organic extracts were evaporated to give a crude product, which was further purified by a silica gel column chromatography.
General Procedure of Boc-Deprotection
A solution of Boc-protected compound in 18% HCl in 1,4-dioxane (20 mL) was stirred for 4 h at 25˝C (TLC control). The solvent was removed in vacuo, the residue was triturated with ethyl acetate; a precipitate was filtered off, washed with ethyl acetate and dried.
General Procedure of Acylation
First, 3-Chloro-2-fluoro-benzoic acid (63 mg, 0.36 mmol), TBTU (116 mg, 0.36 mmol), amine dihydrochloride (0.3 mmol) and triethylamine (0.168 mL, 1.2 mmol) were dissolved in dry acetonitrile (5 mL). The mixture was stirred for 8 h at room temperature (TLC control). After the reaction was completed the mixture was concentrated to dryness in vacuo. Residue was treated with 10% potassium carbonate (10 mL). The resulting mixture was extracted with dichloromethane (2ˆ20 mL), organic extract was concentrated and purified by column chromatography. 4-Carbamoylmethyl-piperidine-1-carboxylic acid tert-butyl Ester (2 1 ). The suspension of 4-carboxymethylpiperidine-1-carboxylic acid tert-butyl ester (1 1 ) (3.04 g, 12.5 mmol), TBTU (4.49 g, 14 mmol), ammonium carbonate (2.4 g, 25 mmol) and triethylamine (5.32 mL, 38 mmol) in dry acetonitrile (80 mL) was stirred for 8 h at room temperature (TLC control). After the reaction was completed the mixture was evaporated to dryness in vacuo. Residue was treated with 10% aqueous solution of potassium carbonate (50 mL). The resulting mixture was extracted with dichloromethane (3ˆ100 mL), organic extract was evaporated. Purification by column chromatography on silica gel (eluent: hexane/ethyl acetate-1/1) afforded (2 1 ) (2.42 g, 83%). 1 4-(4-Hydroxy-6-methyl-pyrimidin-2-ylmethyl)-piperidine-1-carboxylic acid tert-butyl Ester (4 1 ). To a solution of amide (2 1 ) (2.42 g, 10 mmol) in dichloromethane (100 mL), triethyloxoniumtetrafluoroborate (1.78 g, 12 mmol) was added at constant stirring; the resulted mixture was stirred for 2 h at room temperature. Then the reaction mixture was concentrated at~45˝C. The residue was treated with solution of NH 3 /CH 3 OH (pH should be 10), and left to stay overnight. The reaction mixture was evaporated to dryness, and the obtained product (3 1 ) was used in the next step without purification. APCI-MS (m/z (intensity)): 242.1 ([M + H] + , 100%).
Crude compound (3 1 ) was added to a solution of NaO t Bu (1.15 g, 12 mmol) in anhydrous ethanol (100 mL). The mixture was stirred at room temperature for 10 min, and then methyl 3-oxobutanoate (1.95 g, 15 mmol) was added. The resulting mixture was refluxed for 10 h (TLC control). Then the reaction mixture was concentrated under reduced pressure, dissolved in water and acidified with 1 N HCl to pH = 5.0 and extracted with ethyl acetate (2ˆ100 mL). An organic layer was dried over Na 2 SO 4 and concentrated in vacuum. The residue was purified by flash-chromatography on silica gel (eluent: hexane/ethyl acetate-1/1). As a result, compound (4 1 ) (1.99 g, 65%) was obtained. APCI-MS (m/z (intensity)): 308.2 ([M + H] + , 100%).
4-(4-Chloro-6-methyl-pyrimidin-2-ylmethyl)-piperidine-1-carboxylic acid tert-butyl Ester (5 1 ). The compound (4 1 ) (1.99 g, 6.5 mmol) and dimethylaniline (7.08 g, 58.5 mmol) were dissolved in toluene (100 mL). POCl 3 (2.99 g, 19.5 mmol) was added dropwise. The reaction mixture was refluxed for 3 h, cooled down to room temperature and poured into water. Organic layer was separated, washed with 1 N HCl and water. Organic layer was concentrated under reduced pressure and purified with flash chromatography (eluent: hexane/ethylacetate 4/1). Yield 1.3 g (62%). 1 4-[4-Methyl-6-(thiazol-2-ylamino)-pyrimidin-2-ylmethyl]-piperidine-1-carboxylic acid tert-butyl Ester (6 1 a) was prepared using Buchwald reaction, yield 292 mg (75%). 1 4-[4-Methyl-6-(5-methyl-thiazol-2-ylamino)-pyrimidin-2-ylmethyl]-piperidine-1-carboxylic acid tert-butyl Ester (6 1 b) was prepared using Buchwald reaction, yield 290 mg (72%). 1 0.5 mmol) in dichloromethane (20 mL) at room temperature for 4 h. Residue was treated with 10% aqueous solution of potassium carbonate (10 mL). The organic extract was evaporated and purified by column chromatography on silica gel (eluent: hexane/ethyl acetate-4/1) to afford (6 1 c) (148 mg, 70%). 1 4-Methylene-piperidine-1-carboxylic acid tert-butyl Ester (10 1 ). NaH in mineral oil (2.28 g, 57 mmol, 60%) was added portion-wise under argon atmosphere to DMSO (35 mL). The reaction mixture was stirred on a water bath up to 75˝C for about 20 min until completion of hydrogen formation. The reaction mixture was cooled down to 20˝C and treated with methyl triphenylsulfonium iodide (23.1 g, 57 mmol). After stirring for about 15 min, ketone (9 1 ) (9.96 g, 50 mmol) in THF (15 mL) was added. The mixture was stirred at 25˝C for about 2 h and diluted with water, ethyl acetate and hexane. The organic layer was washed with water (2ˆ25 mL), diluted with dichloromethane and washed with brine. The combined aqueous layers were extracted with ethyl acetate (50 mL) and hexane (50 mL). The organic layer was filtered through SiO 2 . The combined filtrate was concentrated and resulted in the title compound. Yield 7.4 g (75%).
4-(6-Bromo-pyridin-2-ylmethyl)-piperidine-1-carboxylic acid tert-butyl Ester (11 1 ). To a solution of alkene (10 1 ) (7.4 g, 37.5 mmol) in 50 mL of anhydrous THF 9-borabicyclo[3.3.1]nonane (90 mL, 0.5 M solution in THF, 45 mmol) was added under argon atmosphere. A resulted solution was stirred at room temperature for 24 h, then 2,6-dibromopyridine (8.9 g, 37.5 mmol), potassium carbonate (7.65 g, 56 mmol), water (15 mL), and catalyst Pd(PPh 3 ) 4 (2.16 g, 1.87 mmol) were added therein. The reaction mixture was refluxed for 4 h, cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2ˆ100 mL). The combined organic extracts were evaporated to give a crude oil, which was purified by a silica gel column chromatography to give the titled compound. Yield 10.3 g (78%). 1 
